Neuren Pharmaceuticals (ASX:NEU) see FDA approval for treatment of Rett syndrome
04 Mar 2020 - Acadia Pharmaceuticals Inc. and Neuren Pharmaceuticals (ASX:NEU) announced today that the US Food and Drug Administration (FDA) granted Rare Pediatric Disease (RPD) designation to trofinetide for the treatment of Rett syndrome, a serious and rare neurological disorder.